➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
McKinsey
McKesson
Colorcon
Mallinckrodt

Last Updated: August 9, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,115,557

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,115,557
Title:Use of certain drugs for treating nerve root injury
Abstract: The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
Inventor(s): Olmarker; Kjell (Molndal, SE)
Assignee: Sciaticon AB (Molndal, SE)
Application Number:10/225,237
Patent Claims:1. A method for treatment of a nerve disorder selected from the group consisting of nerve root injury, sciatica, low back pain, whiplash associated disorder, nucleus pulposus-induced nerve injury, spinal cord compression, cervical rhizopathy, and a nerve disorder caused by a disk herniation in a subject comprising administering to said subject a therapeutically effective dosage of a first TNF inhibitor in combination with a second TNF inhibitor.

2. The method of claim 1, wherein said first TNF inhibitor is a specific TNF inhibitor and said second TNF inhibitor is a non-specific TNF inhibitor.

3. The method of claim 2, wherein said specific TNF inhibitor is infliximab, CDP-571 (Humicade.TM.), D2E7, or CDP-870.

4. The method of claim 2, wherein said specific TNF inhibitor is a soluble cytokine TNF receptor.

5. The method of claim 4, wherein said soluble cytokine TNF receptor is etanercept.

6. The method of claim 2, wherein said non-specific TNF inhibitor is a TNF inhibitor in the form of a binuclear DNA threading transition metal complex with anti-cancer effect.

7. The method of claim 2, wherein said non-specific TNF inhibitor is a TNF inhibitor in the form of a lactoferrin derivable peptide.

8. The method of claim 2, wherein said non-specific TNF inhibitor is an MMP inhibitor.

9. The method of claim 8, wherein said MMP inhibitor is doxycycline.

10. The method of claim 2, wherein said non-specific TNF inhibitor is a p38 kinase inhibitor.

11. The method of claim 2, wherein said non-specific TNF inhibitor is TTP.

12. The method of claim 2, wherein the subject is a vertebrate.

13. The method of claim 12, wherein the vertebrate is a mammal.

14. The method of claim 13, wherein the mammal is a human.

15. The method of claim 2, wherein said inhibitors are administered systemically or locally.

16. The method of claim 2, wherein said inhibitors are administered parenterally.

17. The method of claim 2, wherein said inhibitors are administered intramuscularly, intravenously, subcutaneously, orally, or rectally.

18. The method of claim 17, wherein said inhibitors are administered intravenously by injection or infusion.

19. The method of claim 18, wherein said specific TNF inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg.

20. The method of claim 2, wherein said specific TNF inhibitor is D2E7 and is administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said subject.

21. The method of claim 2, wherein said specific TNF inhibitor is CDP-870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject.

22. A method for treatment of a nerve disorder selected from the group consisting of nerve root injury, sciatica, low back pain, whiplash associated disorder, nucleus pulposus-induced nerve injury, spinal cord compression, cervical rhizopathy, and a nerve disorder caused by a disk herniation in a subject comprising administering to said subject a therapeutically effective dosage of a TNF inhibitor in combination with a IL-1 inhibitor.

23. The method of claim 22, wherein said TNF inhibitor is infliximab, CDP-571 (Humicade.TM.), D2E7, or CDP-870.

24. The method of claim 22, wherein said TNF inhibitor is a soluble cytokine TNF receptor.

25. The method of claim 22, wherein said soluble cytokine TNF receptor is etanercept.

26. The method of claim 22, wherein said TNF inhibitor is a binuclear DNA threading transition metal complex with anti-cancer effect.

27. The method of claim 22, wherein said TNF inhibitor is a lactoferrin derivable peptide.

28. The method of claim 22, wherein said TNF inhibitor is an MMP inhibitor.

29. The method of claim 28, wherein said MMP inhibitor is doxycycline.

30. The method of claim 22, wherein said TNF inhibitor is a p38 kinase inhibitor.

31. The method of claim 22, wherein said TNF inhibitor is TTP.

32. The method of claim 22, wherein said IL-1 inhibitor is anakinra.

33. The method of claim 22, wherein the subject is a vertebrate.

34. The method of claim 33, wherein the vertebrate is a mammal.

35. The method of claim 34, wherein the mammal is a human.

36. The method of claim 22, wherein said inhibitors are administered systemically or locally.

37. The method of claim 22, wherein said inhibitors are administered parenterally.

38. The method of claim 22, wherein said inhibitors are administered intramuscularly, intravenously, subcutaneously, orally, or rectally.

39. The method of claim 38, wherein said inhibitors are administered intravenously by injection or infusion.

40. The method of claim 39, wherein said TNF inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg.

41. The method of claim 22, wherein said TNF inhibitor is D2E7 and is administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said subject.

42. The method of claim 22, wherein said TNF inhibitor is CDP-870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803276Sep 25, 1998
Sweden9803710Oct 29, 1998

Details for Patent 7,115,557

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Centocor Inc REMICADE infliximab VIAL 103772 001 1998-08-24   Start Trial Sciaticon AB (Molndal, SE) 2018-09-25 RX Orphan search
Immunex ENBREL etanercept VIAL; SUBCUTANEOUS 103795 001 1998-11-02   Start Trial Sciaticon AB (Molndal, SE) 2018-09-25 RX Orphan search
Immunex ENBREL etanercept SYRINGE 103795 002 1998-11-02   Start Trial Sciaticon AB (Molndal, SE) 2018-09-25 RX Orphan search
Biovitrum Ab KINERET anakinra VIAL; SUBCUTANEOUS 103950 001 2001-11-14   Start Trial Sciaticon AB (Molndal, SE) 2018-09-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
Express Scripts
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.